Literature DB >> 8399171

Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1).

L C Chen1, M E Noelken, H Nagase.   

Abstract

Matrix metalloproteinases (MMPs) are activated in vitro from their precursors (proMMPs) by multiple means such as treatment with proteinases, mercurial compounds, chaotropic agents, sodium dodecyl sulfate, HOCl, and heat. The latency of proMMPs is stabilized by intramolecular interaction of the single cysteine residue in the conserved sequence PRCG(V/N)PD of the propeptide and the zinc atom at the active site. The activation of proMMP-1 (interstitial procollagenase) by multiple treatments has been explained by the "cysteine switch" model, in which the disruption of the Cys-Zn interaction is considered to be critical for activation [Springman, E. B., Angleton, E. L., Birkedal-Hansen, H., & VanWart, H. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 364-368]. To further test this hypothesis we dissociated the Cys-Zn interaction by specifically modifying Cys-75 of proMMP-3 (prostromelysin 1) with iodoacetamide, (4-aminophenyl)mercuric acetate (APMA), or 5,5'-dithiobis(2-nitrobenzoate) and examined the expression of enzymic activity. The enzymic assays of the modified proMMP-3s against protein and synthetic substrates did not reveal any significant activity. The modified 57-kDa proMMP-3s were stable and did not show spontaneous activation. Activation of the modified proMMP-3s required further treatment with APMA or a proteinase and was accompanied by conversion of the proMMP-3 to a 45-kDa species. Circular dichroism studies of proMMP-3 treated with HgCl2 demonstrated time-dependent conformational changes in proMMP-3 prior to the expression of proteolytic activity and processing of the zymogen to lower molecular weight species. These results indicate that the disruption of the Cys-Zn coordination alone is not sufficient to activate proMMP-3.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399171     DOI: 10.1021/bi00090a003

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 3.  Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-alpha-converting enzyme.

Authors:  Irit Sagi; Marcos E Milla
Journal:  Anal Biochem       Date:  2007-09-26       Impact factor: 3.365

4.  Detrimental effects of discectomy on intervertebral disc biology can be decelerated by growth factor treatment during surgery: a large animal organ culture model.

Authors:  Svenja Illien-Jünger; Young Lu; Devina Purmessur; Jillian E Mayer; Benjamin A Walter; Peter J Roughley; Sheeraz A Qureshi; Andrew C Hecht; James C Iatridis
Journal:  Spine J       Date:  2014-04-24       Impact factor: 4.166

Review 5.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 6.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 7.  The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Authors:  Rugmani Padmanabhan Iyer; Nicolle L Patterson; Gregg B Fields; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

8.  Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice.

Authors:  Saurabh Dahiya; Shephali Bhatnagar; Sajedah M Hindi; Chunhui Jiang; Pradyut K Paul; Shihuan Kuang; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2011-08-16       Impact factor: 6.150

9.  A single step purification for autolytic zinc proteinases.

Authors:  Erin M Wilfong; Ursala Locklear; Eric J Toone
Journal:  Bioorg Med Chem Lett       Date:  2009-11-05       Impact factor: 2.823

Review 10.  Structure and evolutionary aspects of matrix metalloproteinases: a brief overview.

Authors:  Sudip Das; Malay Mandal; Tapati Chakraborti; Amritlal Mandal; Sajal Chakraborti
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.